Trial Profile
Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas After Radiation Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Paxalisib (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma
- Focus Adverse reactions; Pharmacokinetics
- 13 Jan 2023 Status changed from active, no longer recruiting to completed.
- 17 Jun 2022 According to a Kazia Therapeutics media release, final data from this study is expected to be submitted for publication by the end of CY2022.
- 22 Mar 2022 Planned End Date changed from 1 Jun 2024 to 1 Jun 2023.